Teacher Retirement System of Texas Sells 5,855 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Teacher Retirement System of Texas reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,077 shares of the biopharmaceutical company's stock after selling 5,855 shares during the quarter. Teacher Retirement System of Texas' holdings in Regeneron Pharmaceuticals were worth $20,978,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares in the last quarter. Adirondack Trust Co. lifted its stake in Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares in the last quarter. Prestige Wealth Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 23.2% in the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 19 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. UBS Group lowered their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Trading Up 1.8%

Shares of REGN stock traded up $9.64 on Tuesday, hitting $547.75. 847,049 shares of the company's stock traded hands, compared to its average volume of 909,523. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company's fifty day simple moving average is $547.51 and its 200 day simple moving average is $623.07. The stock has a market capitalization of $59.14 billion, a price-to-earnings ratio of 13.94, a P/E/G ratio of 1.98 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the prior year, the business posted $9.55 EPS. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.